ATE246929T1 - Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen - Google Patents

Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen

Info

Publication number: ATE246929T1
Authority: AT; Austria
Prior art keywords: patient; effects; treatment; endothelial lining; vasospastic diseases
Prior art date: 1995-05-05

Application number

AT96911890T

Other languages

English (en)

Inventor

Anthony Ernest Bolton

Ernest Davidson Cooke

Original Assignee

Vasogen Ireland Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-05

Filing date

1996-05-03

Publication date

2003-08-15

1995-05-05 Priority claimed from GBGB9509197.1A external-priority patent/GB9509197D0/en

1995-11-02 Priority claimed from GBGB9522475.4A external-priority patent/GB9522475D0/en

1996-05-03 Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd

2003-08-15 Application granted granted Critical

2003-08-15 Publication of ATE246929T1 publication Critical patent/ATE246929T1/de

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
230000002455 vasospastic effect Effects 0.000 title abstract 2
201000010099 disease Diseases 0.000 title 1
230000000694 effects Effects 0.000 title 1
230000003511 endothelial effect Effects 0.000 title 1
210000004369 blood Anatomy 0.000 abstract 2
239000008280 blood Substances 0.000 abstract 2
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract 1
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 abstract 1
208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
230000008753 endothelial function Effects 0.000 abstract 1
210000000265 leukocyte Anatomy 0.000 abstract 1
230000001590 oxidative effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Developmental Biology & Embryology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Diabetes (AREA)
Immunology (AREA)
Virology (AREA)
Zoology (AREA)
Inorganic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT96911890T 1995-05-05 1996-05-03 Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen ATE246929T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9509197.1A GB9509197D0 (en)	1995-05-05	1995-05-05	Endothelial lining effects
GBGB9522475.4A GB9522475D0 (en)	1995-11-02	1995-11-02	Treatment of raynauds phenomenon
PCT/CA1996/000282 WO1996034613A1 (en)	1995-05-05	1996-05-03	Endothelial lining effects and treatment of vasospastic disorders

Publications (1)

Publication Number	Publication Date
ATE246929T1 true ATE246929T1 (de)	2003-08-15

Family

ID=26306991

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96911890T ATE246929T1 (de)	1995-05-05	1996-05-03	Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen

Country Status (11)

Country	Link
EP (1)	EP0768886B1 (de)
JP (1)	JPH10506636A (de)
AT (1)	ATE246929T1 (de)
AU (1)	AU721530B2 (de)
CA (1)	CA2194485C (de)
DE (1)	DE69629436T2 (de)
DK (1)	DK0768886T3 (de)
ES (1)	ES2205026T3 (de)
NZ (1)	NZ306395A (de)
PT (1)	PT768886E (de)
WO (1)	WO1996034613A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6669965B2 (en)	1992-02-07	2003-12-30	Vasogen Ireland Limited	Method of treating atherosclerosis
US5980954A (en)	1992-02-07	1999-11-09	Vasogen Ireland Limited	Treatment of autoimmune diseases
CA2206180A1 (en) *	1997-05-27	1998-11-27	Vasogen Inc.	Treatment of chronic post-traumatic pain syndromes
NZ503770A (en) *	1997-09-12	2002-10-25	Vasogen Ireland Ltd	Treatment of stress and associated symptoms by stressing blood cells and re-introducing them into the body
US6432399B1 (en)	1997-09-12	2002-08-13	Vasogen Ireland Limited	Treatment of stress and preconditioning against stress
US6264646B1 (en)	1998-11-13	2001-07-24	Vasogen Ireland Limited	Method for preventing and reversing atherosclerosis in mammals
PT1146885E (pt) *	1999-01-12	2003-10-31	Vasogen Ireland Ltd	Pre-condicionamento contra a morte celular
CA2271190A1 (en) *	1999-05-06	2000-11-06	Vasogen Ireland Limited	Improved method for treating mammals with modified mammalian blood
DK1214037T3 (da) *	1999-09-16	2004-08-02	Vasogen Ireland Ltd	Apparat til konditionering af pattedyrsblod
ATE309807T1 (de)	1999-09-24	2005-12-15	Vasogen Ireland Ltd	Zusammensetzung zur behandlung von atherosklerose,welche ein statin und ex-vivo behandeltes blut enthält
CA2309417A1 (en)	2000-05-25	2001-11-25	Anthony E. Bolton	Apoptotic entities for use in treatment of endothelium dysfunction disorders
US7122208B2 (en) *	2001-04-06	2006-10-17	Vasogen Ireland Limited	Compositions containing apoptotic entities

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5100378A (en) *	1989-06-09	1992-03-31	Neorx Corporation	Enhancement of target cell localization of lymphoid cells
AU3506293A (en) *	1992-02-07	1993-09-03	Anthony Ernest Bolton	Method of inhibiting the aggregation of blood platelets
CA2129630C (en) *	1992-02-07	2003-09-23	Anthony E. Bolton	Method of increasing the concentration of nitric oxide in blood
EP0804550A4 (de) *	1994-01-27	1998-08-05	Cellcor Inc	Die ex vivo aktivierung von immunzellen

1996
- 1996-05-03 AT AT96911890T patent/ATE246929T1/de not_active IP Right Cessation
- 1996-05-03 PT PT96911890T patent/PT768886E/pt unknown
- 1996-05-03 JP JP8532887A patent/JPH10506636A/ja active Pending
- 1996-05-03 CA CA002194485A patent/CA2194485C/en not_active Expired - Fee Related
- 1996-05-03 DK DK96911890T patent/DK0768886T3/da active
- 1996-05-03 DE DE69629436T patent/DE69629436T2/de not_active Expired - Fee Related
- 1996-05-03 NZ NZ306395A patent/NZ306395A/en unknown
- 1996-05-03 EP EP96911890A patent/EP0768886B1/de not_active Expired - Lifetime
- 1996-05-03 ES ES96911890T patent/ES2205026T3/es not_active Expired - Lifetime
- 1996-05-03 WO PCT/CA1996/000282 patent/WO1996034613A1/en not_active Ceased
- 1996-05-03 AU AU54944/96A patent/AU721530B2/en not_active Ceased

Also Published As

Publication number	Publication date
NZ306395A (en)	2000-02-28
DE69629436D1 (de)	2003-09-18
DE69629436T2 (de)	2004-06-17
CA2194485C (en)	2001-09-18
AU721530B2 (en)	2000-07-06
EP0768886B1 (de)	2003-08-13
ES2205026T3 (es)	2004-05-01
CA2194485A1 (en)	1996-11-07
JPH10506636A (ja)	1998-06-30
EP0768886A1 (de)	1997-04-23
DK0768886T3 (da)	2003-12-01
WO1996034613A1 (en)	1996-11-07
PT768886E (pt)	2003-12-31
AU5494496A (en)	1996-11-21

Similar Documents

Publication	Publication Date	Title
Cho et al.	2001	Hydrogen peroxide stimulates macrophage vascular endothelial growth factor release
ATE237339T1 (de)	2003-05-15	Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen
ATE399553T1 (de)	2008-07-15	Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ES2071484T3 (es)	1995-06-16	Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
ATE191506T1 (de)	2000-04-15	Gentherapeutische behandlung von gefässerkrankungen durch einen zellspezifischen, zellzyklusabhängigen wirkstoff
ES2080837T3 (es)	1996-02-16	Tratamiento de estados y enfermedades.
DE69533040D1 (de)	2004-06-17	Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
DE69433818D1 (de)	2004-07-01	Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE282425T1 (de)	2004-12-15	Verfahren zur behandlung von endothelialen verletzungen
NO974275D0 (no)	1997-09-16	Fremgangsmåte for behandling av tumorer
ATE281840T1 (de)	2004-11-15	Behandlung von diarrhoe
DE69629436D1 (de)	2003-09-18	Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen
ATE232396T1 (de)	2003-02-15	Oxydiertes thymosin beta 4
DE3582439D1 (de)	1991-05-16	Mittel zur behandlung von herzerkrankungen.
DE69631478D1 (de)	2004-03-11	Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DK0661987T3 (da)	1998-09-14	Morphogeninduceret leverregeneration
DE69634499D1 (de)	2005-04-21	Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration
DE60137146D1 (de)	2009-02-05	Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
DK0841912T3 (da)	2002-11-11	2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
ATE81467T1 (de)	1992-10-15	Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
ES2068714T3 (es)	1995-04-16	Derivados de pirimidina para aumentar la actividad antitumoral.
ES2036526T3 (es)	1993-06-01	Composiciones de interferon.
NO801387L (no)	1980-11-11	Analogifremgangsmaate for fremstilling av terapeutisk aktive morfantridin-derivater
TR199901385T2 (xx)	1999-11-22	Piperidin t�revleri.
ATE309807T1 (de)	2005-12-15	Zusammensetzung zur behandlung von atherosklerose,welche ein statin und ex-vivo behandeltes blut enthält

Legal Events

Date

Code

Title

Description

2004-04-15

UEP

Publication of translation of european patent specification

Ref document number: 0768886

Country of ref document: EP

2008-02-15

REN

Ceased due to non-payment of the annual fee